Perioperative management of patients receiving oral anticoagulants - A systematic review

被引:314
作者
Dunn, AS
Turpie, AGG
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
关键词
D O I
10.1001/archinte.163.8.901
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: The safety and efficacy of various management strategies for patients receiving oral anticoagulants (OACs) who need to undergo surgery or invasive procedures are unknown. Methods: We performed a systematic review and synthesis of the English-language literature examining the perioperative management and outcomes of patients receiving long-term OAC therapy. Results: Thirty-one reports were identified. The quality of the identified reports was generally poor; no randomized controlled trials have been performed and duration of follow-up was typically not stated. Overall, 29 thromboembolic events occurred amont 1868 patients (1.6%; 95% confidence interval, 1.0%-2.1%), including 7 strokes (0.4%; 95% confidence interval, 0%-0.7%). Thromboembolic event rates by management strategy were 0.4% (1 of 237) for continuation of OAC, 0.6% (6 of 996) for discontinuation of OAC therapy without administration of intravenous heparin, 0% (0 of 166) for discontinuation of OAC therapy with administration of intravenous heparin, 0.6% (1 of 180) for discontinuation of OAC therapy with administration of low-molecular-weight heparin, and 8.0% (21 of 263) for unspecified or unclear strategies. Major bleeding while receiving therapeutic OAC was rare for dental procedures (0.2% [4 of 2014]), arthrocentesis (0% [0 of 32]), cataract surgery (0% [0 of 203]), and upper endoscopy or colonoscopy with or without biopsy (0% [0 of 111]). Conclusions: Most patients can undergo dental procedures, arthrocentesis, cataract surgery, and diagnostic endoscopy without alteration of their regimen. For other invasive and surgical procedures, oral anticoagulation needs to be withheld, and the decision whether to pursue an aggressive strategy of perioperative administration of intravenous heparin or subcutaneous low-molecular-weight heparin should be individualized. The current literature is substantially limited in its ability to help choose an optimal strategy. Further and more rigorous studies are needed to better inform this decision.
引用
收藏
页码:901 / 908
页数:8
相关论文
共 67 条
[1]
INCREASED ANTI-XA BIOAVAILABILITY FOR A LOW-MOLECULAR WEIGHT HEPARIN (PK-10169) COMPARED WITH UNFRACTIONATED HEPARIN [J].
BARA, L ;
BILLAUD, E ;
KHER, A ;
SAMAMA, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (03) :316-317
[2]
BENDETOWICZ AV, 1994, THROMB HAEMOSTASIS, V71, P305
[3]
Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents - A prospective study [J].
Billingsley, EM ;
Maloney, ME .
DERMATOLOGIC SURGERY, 1997, 23 (05) :381-383
[4]
BLAJCHMAN MA, 1989, ANN NY ACAD SCI, V556, P245
[5]
MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA BY TRANSURETHRAL LASER-ABLATION IN PATIENTS TREATED WITH WARFARIN ANTICOAGULATION [J].
BOLTON, DM ;
COSTELLO, AJ .
JOURNAL OF UROLOGY, 1994, 151 (01) :79-81
[6]
CADROY Y, 1989, J LAB CLIN MED, V114, P349
[7]
Warfarin in anticoagulation in the perioperative period: Is it safe? [J].
Caliendo, FJ ;
Halpern, VJ ;
Marini, CP ;
Nathan, IM ;
Patel, D ;
Faust, G ;
Cohen, JR .
ANNALS OF VASCULAR SURGERY, 1999, 13 (01) :11-16
[8]
THROMBOEMBOLIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART-VALVE PROSTHESES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
BRIET, E .
CIRCULATION, 1994, 89 (02) :635-641
[9]
Carrel TP, 1999, J HEART VALVE DIS, V8, P392
[10]
CARTER CJ, 1982, BLOOD, V59, P1239